Abstract: A method for the qualification and selection of manufacturing processes, raw materials, intermediates and batch production of pentosan polysulfate based on the identification of acetylated monosaccharide units, including units of xylose substituted with 4-O-methyl-glucuronic which also lead the acetyl group, as structural characterizing units, is disclosed.

Abstract: Dermal filling materials and techniques are disclosed herein. In particular, dermal fillers containing low melt agarose (i.e., agarose having a melting temperature of less than 65° C.) are described. The disclosed dermal fillers can be manipulated after injection by, for example, heating and/or cooling the dermal filler while inside the patient to adjust its positioning or stiffness.

Abstract: The present invention is related to a compound conjugating a drug with a glycosaminoglycan, such as hyaluronic acid (HA), where the drug is useful for the treatment of diseases such as inflammation, auto-immune disease, allergy, infection and preferably cancer. The conjugated compound of the present invention can increase the concentration of drug at the specific site of disease by an interaction of the glycosaminoglycan used as target drug delivery carrier and the CD44 cell surface receptor, then enhancing the therapeutic efficacy and reducing the systemic side effect of the site-delivered drug.

Abstract: Poly alpha-1,3-glucan ester compounds are disclosed herein with a degree of substitution of about 0.001 to about 3.0. Also disclosed are methods of producing poly alpha-1,3-glucan ester compounds using cyclic organic anhydrides.

Abstract: The invention provides a low-molecular-weight (15 kDa) over-sulfated exopolysaccharide (GYS15) prepared from a marine native exopolysaccharide excreted by a mesophilic marine bacterium from a deep-sea hydrothermal environment, and relates to the use of this low-molecular-weight over-sulfated exopolysaccharide for the prevention or inhibition of metastases formation.

Abstract: Presented herein, inter alia, are novel methods of treating heart diseases.

Abstract: A method for producing P1,P4-di(uridine 5?-)tetraphosphate (UP4U) that can avoid reduction of the synthetic efficiency without using UTP free is developed. A method for producing UP4U comprising reacting a phosphoric acid-activating compound represented by formula [II] or [III] with a phosphoric acid compound selected from the group consisting of UMP, UDP, UTP and a pyrophosphoric acid or a salt thereof (excluding UTP free) in water or a hydrophilic organic solvent, in the presence of a metal ion selected from the group consisting of an iron (II) ion, an iron (III) ion, a trivalent aluminum ion, a trivalent lanthanum ion, and a trivalent cerium ion. where, in the formula [II], R1 represents a uridyl group binding to the 5?-position, X represents a heterocyclic group, and n represents an integer of 1 or 2, where, in the formula [III], X represents a heterocyclic group selected from the group consisting of an imidazolyl group, a benzimidazolyl group, and a 1,2,4-triazolyl group.

Abstract: A process for preparing a composition (C1) represented by the formula (I): HO—CH2—(CHOH)n—CH2—O-(G)x-H, in which G represents the remainder of a reducing sugar, n is an integer equal to 2, 3 or 4 and x, which indicates the mean degree of polymerization of the remainder G, represents a decimal number greater than 1 and less than or equal to 5, characterized in that the process includes at least one step a) of reacting a polyol of formula (A1): HO—CH2—(CHOH)n—CH2—OH, in which n is an integer equal to 2, 3 or 4, with a reducing sugar of formula (II): HO-G-H, in which G represents the remainder of a reducing sugar, in the presence of an acid catalyst (Ca), and in that the acid catalyst (Ca) is chosen from phosphorous acid, phosphoric acid and polyphosphoric acid.

Abstract: The present invention relates to a compound of dihydrophaseic acid 3?-O-beta-D-glucopyranoside for the prevention and treatment of osteoporosis. It was found that the D3G isolated from the Lycium root bark extract induces the activity of osteoblast differentiation while promoting the proliferation of pre-osteoblast, and promotes the bone remodeling by promoting the differentiation of both osteoblast and osteoclast when mixing and culturing pre-osteoblast which is the precursor of osteoblast, and monocyte which is the precursor of osteoclast. Therefore, the D3G of the present invention is expected to be useful as a pharmacological agent or functional food effective for the prevention and treatment of osteoporosis which is a disease caused by the abnormal balance of bone remodeling.

Abstract: Methods for preparing synthetic heparins are provided. Synthetic heparin compounds, including ultralow molecular weight heparin compounds are provided. Also provided are methods of chemoenzymatically synthesizing structurally homogeneous ultra-low molecular weight heparins. Heparin compounds provided herein can have anticoagulant activity.

Abstract: This invention relates to a flavonoid composition that includes eriocitrin. The flavonoid may be included in a complex with other bioflavonoids. The composition may also include neoeriocitrin. This invention also relates to methods of using the composition, including for reducing IL-6 or MCP-1 treating inflammation, and treating symptoms of metabolic syndrome.

Abstract: The present disclosure relates to 2,6-diaminopurine (DAP) for use in the treatment of a disease caused by a nonsense mutation in a gene, leading to the premature insertion of a UGA stop codon.

Abstract: Disclosed are compositions comprising nicotinamide riboside and a urolithin. The compositions are useful as medicaments, for example, for treating muscle-related pathological conditions, neurodegenerative diseases, and/or mitochondrial diseases, and as dietary supplements, functional foods and beverages, and as specialized nutrition or medical foods.

Abstract: A method of producing crystalline cellulose from a cellulosic material includes the step of reacting the cellulosic material in an aqueous slurry comprising a transition metal catalyst and a hypohalite solution.

Abstract: The present invention relates to a method for degrading a polysaccharide in the field of food, medicine or chemical industry. In particular, a molecular chain of the polysaccharide is broken by ozone into polysaccharides with smaller molecular weights, oligoses and/or oligosaccharides. The polysaccharides include linear or branched glycans extracted from plants, traditional Chinese medicinal materials, animals, fungi, or microorganisms and sulfated polysaccharides or esterified polysaccharides formed by sulfation or esterification thereof. As an oxidizing agent in the reaction, the ozone can be used alone or can be used under the catalysis of a base, a metal ion, hydrogen peroxide, UV light, or activated carbon to accelerate the reaction.

Abstract: A method for making a highly soluble steviol glycoside composition is described. The resulting composition readily provides aqueous solutions with at least 0.3% concentration.

Abstract: Described are voriconazole formulations including 2-hydroxypropyl-?-cyclodextrins and the preparation thereof.

Abstract: This disclosure provides novel saccharide derivatives, conjugates, and methods for making the derivatives and conjugates.

Abstract: Provided is a method for producing hydroxypropyl methyl cellulose (HPMC) having high hydroxypropoxy content, low ash content, and low insoluble fiber content. More specifically, provided is a method for producing HPMC having a methoxy degree of substitution of from 1.4 to 2.2 and a hydroxypropoxy molar substitution of from 0.5 to 1.0, including steps of: bringing sheet-like or chip-like pulp into contact with an alkali metal hydroxide solution to obtain a reaction product mixture containing alkali cellulose, removing a liquid portion from the reaction product mixture to obtain the alkali cellulose, reacting the alkali cellulose with an etherifying agent to obtain a crude HPMC, disintegrating the crude HPMC into a disintegrated crude HPMC, dispersing the disintegrated crude HPMC in water to obtain a slurry, filtering the slurry to obtain a cake, and washing the cake.

Abstract: The invention relates to novel crystalline phases of 5,6-dichloro-2-(isopropylamino)-1-(?-L-ribofuranosyl)-1H-benzimidazole (Maribavir), pharmaceutical compositions thereof and their use in medical therapy.